Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Consensus Target Price of $60.00

Avalyn Pharma Inc. (NASDAQ:AVLN) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $60.00.

A number of analysts recently issued reports on the company. Raymond James Financial assumed coverage on Avalyn Pharma in a research note on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective on the stock. Morgan Stanley raised their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings began coverage on Avalyn Pharma in a report on Thursday, August 13th. They set a “sell (d+)” rating for the company. Finally, Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th.

Avalyn Pharma Price Performance

AVLN opened at $25.53 on Thursday. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $40.17. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.13 billion and a P/E ratio of -1.12. The business’s fifty day moving average price is $33.38.

Avalyn Pharma (NASDAQ:AVLN) last posted its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. As a group, equities analysts anticipate that Avalyn Pharma will post -3.86 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Large investors have recently added to or reduced their stakes in the business. Montanova Capital LLC bought a new position in Avalyn Pharma in the 2nd quarter worth about $82,402,000. Bank of New York Mellon Corp purchased a new position in shares of Avalyn Pharma during the second quarter worth about $1,321,000. Braidwell LP bought a new position in shares of Avalyn Pharma in the second quarter worth approximately $26,382,000. Finally, State Street Corp purchased a new stake in Avalyn Pharma in the second quarter valued at approximately $10,501,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.